Literature DB >> 23117883

CD40-mediated activation of chronic lymphocytic leukemia cells promotes their CD44-dependent adhesion to hyaluronan and restricts CCL21-induced motility.

Tamara Girbl1, Elisabeth Hinterseer, Eva Melanie Grössinger, Daniela Asslaber, Karin Oberascher, Lukas Weiss, Cornelia Hauser-Kronberger, Daniel Neureiter, Hubert Kerschbaum, David Naor, Ronen Alon, Richard Greil, Tanja Nicole Hartmann.   

Abstract

Microenvironmental interactions are crucial for the survival and proliferation of chronic lymphocytic leukemia (CLL) cells. CD4+ T cells that express CD40 ligand (CD40L), along with other accessory immune and stromal cells within CLL lymph nodes, provide signals needed for activation and outgrowth of the tumor clone. Furthermore, correct positioning of CLL cells within lymphoid subcompartments is essential for the transmission of these supportive signals. Thereby, interstitial cell migration and adhesion events, influenced by activational stimuli, determine CLL cell localization. CD44 has been implicated in cell activation, migration, and tissue retention via binding to its extracellular matrix ligand hyaluronan (HA). In this study, we investigated the role of CD44-HA interactions for CLL positioning and interaction with supportive microenvironments in peripheral lymph nodes, focusing on its regulation via CD40L-dependent, T-cell-mediated activation of CLL cells. We found that hyaluronan triggered a robust CCL21-induced motility of resting CLL cells. However, CD40L stimulation promoted the firm, CD44-mediated adhesion of CLL cells to hyaluronan, antagonizing their motile behavior. N-linked glycosylations of CD44, particularly associated with the variant isoform CD44v6 after CD40L activation, seemed to facilitate hyaluronan recognition by CD44. We propose that the CD40L-CD40 signaling axis provides a stop signal to motile CLL cells within lymph node compartments by inducing high avidity CD44-HA adhesion. This might retain CLL cells close to T-cell stimuli and facilitate essential interactions with hyaluronan-bearing stromal cells, collectively promoting CLL cell proliferation and survival.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23117883     DOI: 10.1158/0008-5472.CAN-12-2749

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  19 in total

1.  A novel CD44-binding peptide from the pro-matrix metalloproteinase-9 hemopexin domain impairs adhesion and migration of chronic lymphocytic leukemia (CLL) cells.

Authors:  Estefanía Ugarte-Berzal; Elvira Bailón; Irene Amigo-Jiménez; Juan Pablo Albar; José A García-Marco; Angeles García-Pardo
Journal:  J Biol Chem       Date:  2014-04-16       Impact factor: 5.157

2.  Akt Signaling Is Sustained by a CD44 Splice Isoform-Mediated Positive Feedback Loop.

Authors:  Sali Liu; Chonghui Cheng
Journal:  Cancer Res       Date:  2017-05-22       Impact factor: 12.701

3.  Microenvironment-induced CD44v6 promotes early disease progression in chronic lymphocytic leukemia.

Authors:  Julia C Gutjahr; Eva Szenes; Lisa Tschech; Daniela Asslaber; Michaela Schlederer; Simone Roos; Xiaobing Yu; Tamara Girbl; Christina Sternberg; Alexander Egle; Fritz Aberger; Ronen Alon; Lukas Kenner; Richard Greil; Veronique Orian-Rousseau; Tanja N Hartmann
Journal:  Blood       Date:  2018-01-19       Impact factor: 22.113

4.  CD44 is a RAS/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosis.

Authors:  Niklas Mueller; Daniel Wicklein; Gregor Eisenwort; Mohamad Jawhar; Daniela Berger; Gabriele Stefanzl; Georg Greiner; Alexandra Boehm; Christoph Kornauth; Leonhard Muellauer; Susanne Sehner; Gregor Hoermann; Wolfgang R Sperr; Philipp B Staber; Ulrich Jaeger; Johannes Zuber; Michel Arock; Udo Schumacher; Andreas Reiter; Peter Valent
Journal:  Blood       Date:  2018-07-17       Impact factor: 22.113

5.  Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells.

Authors:  Kathleen J Till; Andrew R Pettitt; Joseph R Slupsky
Journal:  J Immunol       Date:  2015-01-28       Impact factor: 5.422

Review 6.  The Role of CD44 in the Pathophysiology of Chronic Lymphocytic Leukemia.

Authors:  Julia Christine Gutjahr; Richard Greil; Tanja Nicole Hartmann
Journal:  Front Immunol       Date:  2015-04-20       Impact factor: 7.561

Review 7.  Revealing the Mechanisms of Protein Disorder and N-Glycosylation in CD44-Hyaluronan Binding Using Molecular Simulation.

Authors:  Olgun Guvench
Journal:  Front Immunol       Date:  2015-06-16       Impact factor: 7.561

8.  Total proteome analysis identifies migration defects as a major pathogenetic factor in immunoglobulin heavy chain variable region (IGHV)-unmutated chronic lymphocytic leukemia.

Authors:  Gina L Eagle; Jianguo Zhuang; Rosalind E Jenkins; Kathleen J Till; Puthen V Jithesh; Ke Lin; Gillian G Johnson; Melanie Oates; Kevin Park; Neil R Kitteringham; Andrew R Pettitt
Journal:  Mol Cell Proteomics       Date:  2015-02-02       Impact factor: 5.911

9.  Macrophage-mediated chronic lymphocytic leukemia cell survival is independent of APRIL signaling.

Authors:  Mha van Attekum; S Terpstra; E Reinen; A P Kater; E Eldering
Journal:  Cell Death Discov       Date:  2016-03-21

10.  Metformin inhibits cell cycle progression of B-cell chronic lymphocytic leukemia cells.

Authors:  Silvia Bruno; Bernardetta Ledda; Claudya Tenca; Silvia Ravera; Anna Maria Orengo; Andrea Nicola Mazzarello; Elisa Pesenti; Salvatore Casciaro; Omar Racchi; Fabio Ghiotto; Cecilia Marini; Gianmario Sambuceti; Andrea DeCensi; Franco Fais
Journal:  Oncotarget       Date:  2015-09-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.